Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.51 |
| ▸ | REN | P00797 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PEPD | P12955 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177826 | 1.00 | ACE (0.51) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL5966124 | 0.94 | ACE (0.46) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL3931067 | 0.85 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL109013 | 0.85 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL5013232 | 0.85 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL9166405 | 0.85 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL428477 | 0.83 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL358379 | 0.83 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL428476 | 0.83 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL6789463 | 0.83 | ACE (0.47) | ACERENLMNAHSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196065-B2 | Enteral formulation | ERNEST STEPHEN P | 2007-03-27 | — | — | US | claimed |
| US-20050070498-A1 | Enteral formulation | ERNEST STEPHEN P (US) | 2005-03-31 | — | — | US | claimed |
| US-20030148933-A1 | Derivatives of dehydrodidemnin B | PHARMA MAR S.A. (ES) | 2003-08-07 | — | — | US | claimed |
| US-6221836-B1 | Composition of pyruvate and anabolic protein and method for increasing fat loss in a mammal | PAXTON KING BEALE | 2001-04-24 | — | — | US | claimed |
| US-6153731-A | REACTING DIDEMNIN A WITH PYRUVYL-PROLINE AND SEPARATING THE RESULTING DEHYDRODIDEMNIN B FROM THE REACTION MIXTURE | PHARMA MAR, S.A. (ES) | 2000-11-28 | — | — | US | claimed |
| US-6008252-A | Method for increasing muscle mass in a mammal | BEALE PAXTON K (US) | 1999-12-28 | — | — | US | claimed |
| US-5919767-A | ADJUST PROTEIN CONCNETRATION IN MUSCLES | PAX BEALE AND SOPHIE TAGGART TRUST DATED AUGUST 26, 1997, THE | 1999-07-06 | — | — | US | claimed |
| US-5756469-A | SYNERGISTIC COMPOSITION FOR ENTERIC ADMINISTRATION | PAX BEALE AND SOPHIE TAGGART TRUST DATED AUGUST 26, 1997, THE | 1998-05-26 | — | — | US | claimed |
| US-5716926-A | ENHANCING THE PHYSICAL ENDURANCE OF MAMMAL BY ADMINISTERING TO MAMMAL THE ANABOLIC PROTEIN AND PYRUVATE | Beale, Paxton K. (US) | 1998-02-10 | — | — | US | claimed |
| EP-0493480-B1 | DEHYDRODIDEMNIN B | PHARMA MAR SA (ES) | 1996-01-17 | — | — | EP | claimed |
| EP-0493480-A1 | DEHYDRODIDEMNIN B. | RUFFLES GRAHAM KEITH (GB) | 1992-07-08 | — | — | EP | claimed |
| WO-1991004985-A1 | DEHYDRODIDEMNIN B | PHARMA MAR S.A. (ES) | 1991-04-18 | — | — | WO | claimed |
| US-20230048219-A1 | PROCESS FOR CONVERTING AMIDE TO AMINE | RHODIA OPERATIONS (FR) | 2023-02-16 | — | — | US | disclosed |
| US-20220411379-A1 | METHOD FOR PRODUCING EPSILON-CAPROLACTAM | TORAY INDUSTRIES, INC. (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-4069670-A1 | PROCESS FOR CONVERTING AMIDE TO AMINE | RHODIA OPERATIONS (FR) | 2022-10-12 | — | — | EP | disclosed |
| EP-4063345-A1 | METHOD FOR PRODUCING e-CAPROLACTAM | Toray Industries, Inc. (JP) | 2022-09-28 | — | — | EP | disclosed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | disclosed |
| US-4431644-A | CARDIOVASCULAR DISORDERS; DIURETICS | SCHERING CORPORATION (US) | 1984-02-14 | — | — | US | disclosed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048219-A1 | PROCESS FOR CONVERTING AMIDE TO AMINE | SUV39H2, SUV39H1, H1-4 | ACE 444/4885REN 752/4885LMNA 3798/4885 |
| US-20030148933-A1 | Derivatives of dehydrodidemnin B | DHCR7, HSD11B1, HSD11B2 | ACE 927/4885REN 758/4885LMNA 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.